SIGA Technologies Reports Q3 Financial Results, Generates $86M in Product Revenues, $33M in Pre-Tax Operating Income for 2025

SIGA Technologies reported $86 million in product revenues and $33 million in pre-tax operating income for the first nine months of 2025. The company generated $53 million of oral TPOXX revenues and $26 million of IV TPOXX revenues in connection with deliveries to the U.S. Strategic National Stockpile. TPOXX received regulatory approval in Japan for the treatment of smallpox, mpox, cowpox, and complications following smallpox vaccination in adults and pediatric patients weighing at least 13 kg.